The primary objective of this study is to compare overall survival (OS) in participantsreceiving xaluritamig plus abiraterone against investigator's choice (docetaxel,cabazitaxel, or abiraterone).
The primary objective of this study is to compare overall survival (OS) in participantsreceiving xaluritamig plus abiraterone against investigator's choice (docetaxel,cabazitaxel, or abiraterone).
